Stay updated with breaking news from Improved Clinical. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
New Dexcom product with 15-day wear, a cash-pay option and a tailored software experience for people who don't use insulin is expected to launch in the U.S. in 2024 Access and availability of Dexcom CGM is expanding
/PRNewswire/ -- The "Innovations and Growth Opportunities in Respiratory and Cardiac Management Devices, MRI and Digital Health Solutions" report has been...
(PLX AI) - Abbvie Second Phase 3 Induction Study Confirms Upadacitinib (RINVOQ) Improved Clinical and Endoscopic Outcomes in Patients with Crohn's Disease.• In U-EXCEL, the second of two Phase 3 induction
24.02.2022 - (PLX AI) – Abbvie Second Phase 3 Induction Study Confirms Upadacitinib (RINVOQ) Improved Clinical and Endoscopic Outcomes in Patients with Crohn's Disease.In U-EXCEL, the second of two Phase 3 induction studies, a significantly higher proportion of ...
/PRNewswire/ -- The "Emerging Orthopedic Implants: Technology Innovation and Growth Opportunities" report has been added to ResearchAndMarkets.com's offering....